Compare FRGT & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRGT | VRAX |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | Mexico | United Kingdom |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6M | 1.5M |
| IPO Year | 2021 | 2021 |
| Metric | FRGT | VRAX |
|---|---|---|
| Price | $0.25 | $1.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 18.1M | 151.6K |
| Earning Date | 10-27-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 96.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,728,922.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.21 | $0.10 |
| 52 Week High | $5.90 | $13.19 |
| Indicator | FRGT | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 28.60 | 27.96 |
| Support Level | N/A | $0.16 |
| Resistance Level | $1.18 | $3.01 |
| Average True Range (ATR) | 0.09 | 0.28 |
| MACD | 0.06 | -0.05 |
| Stochastic Oscillator | 8.20 | 0.58 |
Freight Technologies Inc is a technology company developing solutions to optimize and automate the supply chain process. Along with its subsidiary, Freight App, Inc, the group is focused on making shipping transparent and efficient. Fr8App provides carriers with increased growth opportunities and shippers with flexibility, visibility, and simplicity for the once-complex process of international over-the-road (OTR) shipping. The company uses its proprietary technology platform to connect carriers and shippers and significantly improve matching and operation efficiency via technologies such as live pricing and real-time tracking, digital freight marketplace, broker, transportation management, fleet management, and committed capacity solutions.
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.